1ameligible for Herpes Zoster vaccination at age 70 in the UK

The UK’s own eligibility rules are the only thing that matters here, and they are narrower than the marketing suggests.

You are 70, so yes, you are eligible for the shingles vaccine on the NHS. The UK schedule offers it routinely at 65 and 70, and then again at 78 and 80. If you missed it at 65, you can still get it at 70. That is the plain answer to the eligibility question. The vaccine offered is Shingrix, the recombinant one, not the old live vaccine Zostavax, which the NHS stopped using in 2023. You do not need to ask your GP for a special reason. You just book it.

But eligibility is not the same as a recommendation, and the difference matters. The NHS will give you two doses, about two months apart. The clinical trials, funded by the manufacturer GSK, showed about 97% protection against shingles in people over 50 in the first year, dropping to about 87% by year four. Those are real numbers from a randomized trial with hard endpoints, so they are not nothing. The problem is what the trials did not measure. They followed people for about four years on average. There is no long-term safety data beyond that. The vaccine contains an adjuvant called AS01, which is a mix of a bacterial saponin and a fat molecule. It is designed to provoke a strong inflammatory response, which is why so many people get fever, chills, and a sore arm for a day or two. That inflammation is not trivial. It is the same kind of immune alarm that, in some people, has been linked to Guillain-Barré syndrome. The FDA and EMA both flagged a small but real signal for that after the vaccine was rolled out. The numbers are tiny, maybe one extra case per million doses, but the signal is there, and the manufacturer’s own post-marketing studies confirmed it.

Now the harder question. Is the vaccine worth it for you? Shingles itself is a painful rash caused by the varicella virus reactivating from your nerves. The risk of getting it rises with age, and the risk of long-term nerve pain, postherpetic neuralgia, rises too. About 1 in 4 people who live to 85 will get shingles at some point. The vaccine cuts that risk substantially. So for a healthy 70-year-old, the benefit is real. But the vaccine is not a free pass. The protection wanes. By year eight, the trial data shows efficacy dropping to around 80%, and some independent modeling suggests it falls faster in older people. You are not getting a lifetime shield. You are getting a few years of reduced risk, and you are paying for it with a deliberate immune storm and a small but nonzero chance of a serious neurological event.

The system will not tell you this. The NHS leaflet says the vaccine is safe and effective, and that is true in the narrow sense of the trial data. But the trial data is manufacturer-funded, the follow-up is short, and the safety surveillance is passive. VAERS and its UK equivalent, the Yellow Card scheme, catch maybe 1 in 10 serious reactions. The absence of reports is not evidence of absence. So when you weigh it, do not let the word "eligible" do the thinking for you. You are eligible. That is a fact. Whether you take it is a judgment about your own body, your own risk of shingles, and your own tolerance for a vaccine that is proven to work in the short term and unproven in the long term. If you have a history of autoimmune disease, especially anything neurological, the risk calculus shifts against it. If you are generally healthy and hate the idea of nerve pain, the calculus shifts toward it. The evidence is clear on the short-term benefit and thin on the long-term harm. That is the honest position, and it is the one the NHS will not give you.